MULTIFACTORIAL ANALYSIS OF MALIGNANT ASCITES: ETIOLOGICAL FACTORS AND PROGNOSTIC DETERMINANTS IN A LARGE HOSPITAL COHORT

Authors

  • I. D. BABOI Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
  • Maria NEDELCU Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
  • Claudia Georgeta IACOBESCU Sf. Ioan Clinical and Emergency Hospital Bucharest, Romania
  • Andreea Taisia TIRON Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
  • Alice Lavinia BĂLĂCEANU Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
  • Valeria Ioana GRIGORESCU Sf. Ioan Clinical and Emergency Hospital Bucharest, Romania
  • I. DINA Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

DOI:

https://doi.org/10.22551/

Abstract

Carcinomatous ascites is a manifestation of advanced-stage disease that can arise from various malignancies, most commonly digestive cancers. This study analyzes the impact of ascites development on disease progression, survival outcomes and several prognostic factors. Materials and methods: This is an observational and retrospective study of 1,470 patients diagnosed with ascites, irrespective of etiology, admitted to the Gastroenterology and Internal Medicine Clinic of Sf. Ioan Clinical and Emergency Hospital Bucharest, a Romanian Tertiary Hospital, during 2015-2023. This study aimed to provide a comprehensive statistical analysis of patient characteristics and etiological factors associated with ascites, focusing on malignant ascites. Results: Malignant ascites was identified in approximately 10% of patients with ascites and was significantly more frequent in association with digestive malignancies compared with extradigestive tumors. Tumors of digestive origin-particularly hepatic cancers-was markedly more often associated with ascites, while extradigestive neoplasms showed a substantially lower incidence. The presence of ascites was strongly associated with malignancy, patients with ascites having a significantly higher prevalence of cancer compared with those without ascites. Conclusions: The findings regarding patients with malignant ascites were contextualized considering local patterns of disease etiology, which may influence prognosis and clinical outcomes.

Author Biographies

  • I. D. BABOI, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

    Sf. Ioan Clinical and Emergency Hospital Bucharest, Romania

  • Alice Lavinia BĂLĂCEANU, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

    Sf. Ioan Clinical and Emergency Hospital Bucharest, Romania

  • I. DINA, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

    Sf. Ioan Clinical and Emergency Hospital Bucharest, Romania

References

1. Moore CM, Van Thiel DH. Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol 2013; 5(5): 251-263 / doi: 10.4254/wjh.v5.i5.251.

2. Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122-128 / doi: 10.1002/hep.1840070124.

3. Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006; 4: 1385-1394 / doi: 10.1016/j.cgh.2006.08.007.

4. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006; 42: 589-597 / doi: 10.1016/j.ejca.2005.11.018.

5. Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of Cirrhosis and Ascites. N Engl J Med 2004; 350: 1646-1654.

6. Biggins S, Angeli P, Garcia‐Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Sponta-neous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Asso-ciation for the Study of Liver Diseases. Hepatology 2021; 74(2): 1014-1048 / doi: 10.1002/hep. 31884.

7. A Cárdenas 1, R Bataller, V Arroyo. Mechanisms of ascites formation. Clin Liver Dis. 2000; 4(2): 447-465 / doi: 10.1016/s1089-3261(05)70118-5.

8. Carrier P, Loustaud-Ratti V, Debette-Gratien M, Elkrief L. Ascites in cirrhotic patients: a comprehen-sive review. ExplorDig Dis 2024; 3: 362-381 / doi: 10.37349.

9. Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepa-torenal syndrome in cirrhosis. Hepatology 1996; 23: 164-176.

10. Omer S, Zara O, Iacobescu C, Dina I. Partial Splenic Embolization for Hypersplenism in Cirrhotic Patients. A Case Series. J Gastrointestin Liver Dis 2014; 23(2): 215-218.

11. Berger JM, et al. Malignant ascites: Current therapy options and treatment prospects. Cancer Treatment Reviews 2023; 121:102646.

12. Jacob R, Sangeerthana A, Razack NA, Prabhuswamimath SC Malignancy of Malignant Ascites: A Comprehensive Review of Interplay between Biochemical Variables, Tumor Microenvironment and Growth Factors. Asian Pac J Cancer Prev 2024; 25(10): 3413-3420.

13. Suma L Sangisetty, Thomas J Miner. Malignant ascites: A review of prognostic factors, pathophysi-ology and therapeutic measures. World J Gastrointest Surg 2012; 4(4): 87-95.

14. 14.Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF. Pathogenesis of malignant ascites formation: initiating events that leadto fluid accumulation. Cancer Res 1993; 53: 2631-2643.

15. Rakina M, Kazakova A, Villert A, Kolomiets L, Larionova I. Spheroid formation and peritoneal metastasis in ovarian cancer: The role of stromal and immune components. Int J Mol Sci 2022; 23(11) / doi: 10.3390/ ijms23116215.

16. Ikegami t, Ishiki H, Kadono T, Ito T, Yokomichi N. Narrative review of malignant ascites: epidemi-ology, pathophysiology, assessment, treatment. Ann Palliat Med 2024; 13(4): 842-857 / doi: 10.21037 /apm-23-554.

17. Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF. Pathogenesis of malignant ascites formation: initiat-ing events that lead to fluid accumulation. Cancer Res 1993; 53(11): 2631-2643.

18. van Baal, JOAM van Noorden CJF, Nieuwland R Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. J Histochem Cytochem 2018; 66(2): 67-83 / doi: 10.1369/0022155 417742897.

19. Kenny HA, Chiang CY, White EA, et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest 2014; 124(10): 4614-4628.

20. Vrabie CD, Petrescu A, Waller W, Dina I. Clinical factors and biomarkers in ovarian tumors devel-opment. Romanian Journal of Morphology and Embryology 2008; 49(3): 327-338.

21. Rakina M, Kazakova A, Villert A, et al. Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components. Int J Mol Sci 2022; 23(11): 6215 / doi: 10.3390/ijms23116215.

22. Klos D, Riško J, Hanuliak J, Peritoneal Carcinomatosis from Ovarian Cancer - Current Clinical Impact of Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy. Klin Onkol 2019; 32(5): 349-352 / doi: 10.14735/amko2019349.

23. Miceli V, et al. Imaging of Peritoneal Carcinomatosis in Advanced Ovarian Cancer: CT, MRI, Radi-omic Features and Resectability Criteria. Cancers 2023; 15: 5827 / doi: 10.3390/cancers15245827.

24. Lheureux S, Braunstein M, Oza A. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 2019; 69: 280-304 / doi: 10.3322/caac.21559.

25. Meucci R, et al. Peritoneal Carcinomatosis of Malignant Gynecological Origin: A Systematic Review of Imaging Assessment. J Clin Med 2024; 13(5): 1254 / doi: 10.3390/ jcm13051254.

26. Bălăceanu LA, Grigore C, Dina I, et al. CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations. J Clin Med 2025; 14: 4152 / doi: 10.3390/jcm 14124152.

27. Van’t Land F, Derikx L, et al. The burden of peritoneal metastases from gastric cancer: a systematic review. J Clin Med 2020; 10(21): 4882 / doi: 10.3390/jcm10214882.

28. Van der Hoeven JJM, Van Hillegersberg R, et al. Gastric adenocarcinoma peritoneal carcinomatosis: a narrative review. Discov Med 2022; 5: 37 / doi: 10.21037/dmr-21-94.

29. Duarte I, Outerelo C. Gastric Cancer Presenting as Isolated Ascites: A Diagnostic Challenge. Eur J Case Rep Intern Med 2019; 6(7): 001141 / doi: 10.12890/2019_001141.

30. Yeldan E , Oguz S, Usta U, Ilhan E, Senlikci A. Risk factors for peritoneal dissemination of gastric cancer. Minerva Chir 2015; 70(2): 91-96.

31. Maeda H, Kobayashi M, Sakamoto J. Evaluation and treatment of malignant ascites secondary to gastric cancer. World J Gastroenterol 2015; 21(39): 10936-10947 / doi: 10.3748/wjg.v21.i39.10936.

32. Andrei P, Battuello P, Grasso G, et al. Integrated Approaches for Precision Oncology in Colorectal Cancer: The More You Know, the Better. Semin. Cancer Biol 2022; 84: 199-213.

33. Vrabie C, Ceausu M, Petrescu A, Waller M, Dina I. The usefulness of immunohisto-chemistry in sporadic colorectal cancer. Romanian Journal of Morphology and Embryology 2008; 49(4): 525-535.

34. Baratti D, Kusamura S, Pietrantonio F, et al. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015: A systematic review. Crit Rev Oncol Hematol 2016; 100: 209-222.

35. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-1422.

36. Szadkowska M, Pałucki J, Cieszanowski A. Diagnosis and Treatment of Peritoneal Carcinomatosis-A Comprehensive Overview. Pol J Radio 2023; 88: 89-97.

37. Capisizu A, Zamfirescu A, Aurelian SM, Dina I. Results of prevalence study regarding comorbidities for various patients. Romanian Statistical Review 2013; 5.

38. Nagaratnam N, Nagaratnam K, Cheuk G. Ascites in the Elderly. In: Geriatric Diseases. Springer, Cham: 2018 / doi: 10.1007/978-3-319-33434-9_21.

39. Balaceanu LA, Dina I. D dimers in advanced cirrhosis: Useful biomarker or not? The American Journal of The Medical Sciences 2024; 368(5): 415-423.

40. Parsons SL, Watson SA, Steele RJ. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997; 23(6): 526-531 / doi: 10.1186/s13148-016-0192-7.

41. Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330: 337-342.

42. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retro-spective study. Ann Oncol Off J Eur Soc Med Oncol (2007; 18(5): 945-949.

43. Ringenberg QS, Doll DC, Loy TS, Yarbro JW. Malignant ascites of unknown origin. Cancer 1989; 64(3): 753-755.

Additional Files

Published

2026-04-01

Issue

Vol. 130 No. 1 (2026): The Medical-Surgical Journal

Section

SURGERY

License

Copyright (c) 2026 The Medical-Surgical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

COPYRIGHT 
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.

COPYRIGHT TRANSFER FORM FOR 

REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /

THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI

We, the undersigned authors of the manuscript entitled

_____________________________________________________________________________________

_____________________________________________________________________________________

warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.

  1. we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
  2. the manuscript does not break the intellectual property rights of any other person.
  3. we have read the submitted version of the manuscript and we are fully responsible for the content.

Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):

  1. ______________________________/_________________________
  2. ______________________________/_________________________
  3. ______________________________/_________________________

N.B.  All the authors must sign this form